(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer proffered paper session included a presentation by Dr. Janet Brown discussing results of the phase II/III STAR trial assessing standard first-line therapy comparing cessation of treatment versus allowing continuation in the treatment of metastatic renal cell carcinoma (RCC). There is increasing interest in using treatment breaks in oncology, to reduce toxicity without compromising efficacy. The STAR trial opened in 2012 in the UK, after sunitinib was approved as the first TKI, and was designed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional continuation strategy in the first line treatment of advanced RCC.